OREANDA-NEWS. August 06, 2013. OJSC Pharmacy Chain 36.6 [RTS: APTK; MICEX: RU14APTK1007] - the leading Russian pharmaceutical retailer announces 1Q 2013 financial results prepared in accordance with the International Financial Reporting Standards (unaudited).

SALES:

Consolidated sales from ongoing operations reached RUR 5 015 mln in 1Q 2013 which is a decrease of 9%;

Net sales in the retail pharmacy segment reached RUR 3 642 mln which is a decrease of 2%;

As of the end of 1Q 2013 Pharmacy Chain 36.6 operated 777 pharmacies in 24 regions;

During 1Q 2013 5 stores were opened organically and 70 stores were closed. As of the end of 1Q 2013 Pharmacy Chain 36.6 operated 8 stand-alone optical outlets and 24 additional optical departments within pharmacies.

PROFIT:

Consolidated gross profit in 1Q 2013 reached RUR 1 983 mln which is a decrease of 15%;

Gross profit of the retail pharmacy segment reached in 1Q 2013 RUR 1 150 mln, which is a decrease of 2%. The gross profit margin in the retail segment in 1Q 2013 equaled to 32% versus 31% in 1Q 2012;

The Company’s consolidated Operating profit reached RUR 360 mln which is a decrease of 9.5% in y-o-y terms. Consolidated selling, general and administrative expenses in 1Q 2013 decreased by 16% and reached RUR 1 623 mln;

The retail pharmacy segment Operating loss in 1Q 2013 reached RUR 112 mln versus RUR 63 mln in 1Q 2012. Retail selling, general and administrative expenses equaled to RUR 1 262 mln;

Consolidated Net loss in 1Q 2013 reached RUR 126 mln versus Net profit of RUR 2 mln in 1Q 2012.
 
FINANCIAL DEBT AND INVESTMENTS

Company’s Net Debt (deducting the remaining monetary funds) equaled to RUR 9 192 mln;

As of the end of 1Q 2013 consolidated financial debt reached RUR 9 628 mln which is a slight decrease of 1% versus the beginning of the year data. Whereas the retail pharmacy debt equaled to RUR 7 743 mln, Veropharm’s debt reached RUR 1 885 mln as of the end of 1Q 2013;

Consolidated finance costs in 1Q 2013 decreased by 11% and reached RUR 346 mln;

Consolidated investments in fixed and intangible assets in 1Q 2013 reached RUR 470 mln, out of which retail investments in opening new pharmacies and re-branding equaled to RUR 62 mln, Veropharm investments reached RUR 402 mln.

VEROPHARM

For the latest update on FY 1Q 2013 performance please refer to the official press-release of the company as of April 30th, 2013 at www.pahrmacychain366.ru.